KMT2A and neoplasm: Although EPZ5676 monotherapy was efficacious for tumor regression in rat MLL-fusion xenografts, the therapeutic efficacy of EPZ5676 depended on the epigenetic repression of MLL target genes, which required continuous IV infusion to maintain the drug concentration in the plasma above a certain threshold [33].